Dong Hu

Prof. Dr. Dong Hu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JZJiawei Zhou
Jiawei Zhou
ACAnqi Cheng
Anqi Cheng
JGJianqiang Guo
Jianqiang Guo
YLYafeng Liu
Yafeng Liu
XLXuan Li
Xuan Li
JWJing Wu
Jing Wu
Triple-negative breast cancer (TNBC) is characterized by high invasiveness, high potential for metastasis, easy recurrence, and poor prognosis. There is an urgent need to develop new clinical treatments. This study utilized TNBC tissue microarrays to detect Peroxiredoxin 2 (PRDX2) expression levels and analyzed the correlation between PRDX2 and tumor invasion as well as invasion-related gene expression through the TCGA database. A stable PRDX2-knockdown triple-negative breast cancer cell line was established using lentiviral technology. The effects of PRDX2 on triple-negative breast cancer cell migration, invasion, and epithelial-mesenchymal transition (EMT) were investigated via wound healing assays, Transwell assays, qPCR, and Western blotting. RNA sequencing (RNA-seq), Western blotting, and dual luciferase reporter assays were performed to confirm that PRDX2 regulates FN1 expression through SP1. Furthermore, subcutaneous tumor xenograft models in nude mice were constructed to assess the effects of PRDX2 knockdown and the PRDX2 inhibitor Conoidin A on tumor growth in vivo. Tissue microarray detection and correlative analysis revealed that PRDX2 is significantly upregulated in triple-negative breast cancer (TNBC) tumor tissues and positively correlated with genes associated with cell migration and invasion. Functional experiments demonstrated that in vitro knockdown of PRDX2 suppresses migration, invasion, and epithelial-mesenchymal transition (EMT) in TNBC cells. Furthermore, in vivo knockdown of PRDX2 or treatment with the PRDX2 inhibitor Conoidin A effectively reduced tumor burden. Mechanistic investigations utilizing RNA sequencing (RNA-seq) identified FN1 as a critical gene promoting TNBC cell migration and invasion. PRDX2 facilitates TNBC progression by activating the PI3K/AKT signaling pathway, which enhances SP1 binding to the FN1 gene promoter. This regulatory cascade ultimately drives tumor advancement in TNBC. This study elucidates the role of the PRDX2/SP1/FN1 axis in TNBC migration and invasion, and highlights PRDX2 as a promising therapeutic target for triple-negative breast cancer.

31 January 2022 in Toxicology
Verified
Journal Article
Closed access
JYJing-Jing Yao
Jing-Jing Yao
QMQian-Qian Ma
Qian-Qian Ma
WSWen-Wen Shen
Wen-Wen Shen
LLLiu-Cheng Li
Liu-Cheng Li
DHDong Hu
Dong Hu

17 July 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YBYing Bai
Ying Bai
CLChao Liang
Chao Liang
JZJiawei Zhou
Jiawei Zhou
YLYafeng Liu
Yafeng Liu
FWFengxuan Wang
Fengxuan Wang
DHDong Hu
Dong Hu

23 June 2024 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
YBYing Bai
Ying Bai
LGLu Gao
Lu Gao
THTao Han
Tao Han
CLChao Liang
Chao Liang
JZJiawei Zhou
Jiawei Zhou
DHDong Hu
Dong Hu

27 June 2024 in Functional & Integrative Genomics
Verified
Journal Article
Closed access
PDF file
THTao Han
Tao Han
YBYing Bai
Ying Bai
YLYafeng Liu
Yafeng Liu
YDYunjia Dong
Yunjia Dong
CLChao Liang
Chao Liang
DHDong Hu
Dong Hu

31 May 2023 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
YBYing Bai
Ying Bai
XZXin Zhang
Xin Zhang
JZJiawei Zhou
Jiawei Zhou
JGJianqiang Guo
Jianqiang Guo
YLYafeng Liu
Yafeng Liu
DHDong Hu
Dong Hu